Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) [Phase 3]

View source ↗

Summary

This Phase 3 trial (COAST 2) evaluated subcutaneous amlitelimab monotherapy versus placebo in participants aged 12 and older with moderate-to-severe atopic derm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Amlitelimab (amlitelimab)

Snippet

Sponsor: Sanofi | Conditions: Dermatitis Atopic | Phase 3 | Status: COMPLETED